Floatz logo

Abesili

Advanced HR+ HER2 Negative Breast Carcinoma

Tianjin Medical University Cancer Institute and HospitalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

224 Active assets in the Advanced HR+ HER2 Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →